Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BY-NCThe oncologist

Treatment of metastatic solid pseudopapillary neoplasms.

  • Courtney Porfido1
  • Diane Reidy-Lagunes2
  • Nitya Raj1
  1. 1Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  2. 2Division of Medical Oncology, Duke Cancer Institute, Durham, NC 27710, United States.
Read full textPDFDOICite

Abstract

Background

Surgical resection is the primary treatment for solid pseudopapillary neoplasms (SPN). Systemic treatment options are limited; no prospective trials or consensus guidelines exist given the rarity of SPN.Patients and methods

We retrospectively reviewed patients treated for SPN at Memorial Sloan Kettering Cancer Center from 2009-2024, summarizing demographics, treatments, outcomes, and genetic testing results when available.Results

Of 45 patients, 42 (93%) underwent surgical resection and 8 (18%) received systemic or locoregional treatment (average 3.25 therapies per patient). Genetic testing was available for 10 patients (22%), 9 of whom had Wnt/β-catenin pathway alterations. One patient whose tumor harbored a CTNNB1 mutation was treated with an investigational therapy inhibiting β-catenin, achieving disease control for 7 months.Conclusion

This is the largest single-institution series of treatment of advanced SPN, demonstrating that select therapies can provide disease control. Molecular characterization of SPN frequently identifies Wnt/β-catenin pathway alterations, demonstrating a potential clinical benefit for drugs targeting this pathway.

Related

  1. Differentiating pancreatic acinar cell carcinoma from solid pseudopapillary neoplasm using contrast-enhanced computed tomography
    Jie Yu, Yingying Cao, Anna Jie +3
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  2. Solid Pseudopapillary Epithelial Neoplasm of the Pancreas: Two Cases and a Review of the Literature
    Vishwaprasad Policepatil, Ankith Reddy Narra, Akhil Sanjay +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Solid Pseudopapillary Neoplasm of the Pancreatic Tail With Splenic Hilar Involvement: A Case Report.
    Kumaresh Pandian, Surya Priya, Arya Sivakumaran +2
    CureusPeer-reviewedCC BYFull textOncologyEurope PMCPMC
  4. Pancreatic head solid-pseudopapillary neoplasm in a man treated by robot-assisted laparoscopic partial pancreatectomy: a case report.
    Rui Ma, Weikang Liu, Yinmo Yang +1
    BMC surgeryPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ
  5. Surgical and functional outcomes of pediatric pancreatic solid pseudopapillary neoplasm: A retrospective study
    Hoan Manh Vu, Hien Duy Pham, Son Cong Nguyen +4
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologySurgery & anaesthesiaPLOS

Cite

BibTeXRIS
BibTeX
@article{porfido2026treatment,
  title = {{Treatment of metastatic solid pseudopapillary neoplasms.}},
  author = {Courtney Porfido and Diane Reidy-Lagunes and Nitya Raj},
  journal = {The oncologist},
  year = {2026},
  month = oct,
  doi = {10.1093/oncolo/oyag393},
  url = {https://europepmc.org/article/MED/42841746},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Treatment of metastatic solid pseudopapillary neoplasms.
AU  - Courtney Porfido
AU  - Diane Reidy-Lagunes
AU  - Nitya Raj
PY  - 2026
DA  - 2026/10/01
JO  - The oncologist
DO  - 10.1093/oncolo/oyag393
UR  - https://europepmc.org/article/MED/42841746
AB  - Background  Surgical resection is the primary treatment for solid pseudopapillary neoplasms (SPN). Systemic treatment options are limited; no prospective trials or consensus guidelines exist given the rarity of SPN.Patients and methods  We retrospectively reviewed patients treated for SPN at Memorial Sloan Kettering Cancer Center from 2009-2024, summarizing demographics, treatments, outcomes, and genetic testing results when available.Results  Of 45 patients, 42 (93%) underwent surgical resection and 8 (18%) received systemic or locoregional treatment (average 3.25 therapies per patient). Genetic testing was available for 10 patients (22%), 9 of whom had Wnt/β-catenin pathway alterations. One patient whose tumor harbored a CTNNB1 mutation was treated with an investigational therapy inhibiting β-catenin, achieving disease control for 7 months.Conclusion  This is the largest single-institution series of treatment of advanced SPN, demonstrating that select therapies can provide disease control. Molecular characterization of SPN frequently identifies Wnt/β-catenin pathway alterations, demonstrating a potential clinical benefit for drugs targeting this pathway.
SN  - 1083-7159
SN  - 1549-490X
ER  -